Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-alpha folate receptor monoclonal antibody - Dompe

Drug Profile

Research programme: anti-alpha folate receptor monoclonal antibody - Dompe

Alternative Names: AFRA; Anti-α-FR Mab; FabOvar

Latest Information Update: 30 Jan 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dompe Farmaceutici
  • Developer Advanced Accelerator Applications; Dompe Farmaceutici
  • Class Monoclonal antibodies
  • Mechanism of Action Folate receptor 1 antagonists; Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Ovarian cancer

Most Recent Events

  • 01 Feb 2018 Advanced Accelerator Applications has been acquired by Novartis
  • 29 Jun 2016 Discontinued - Preclinical for Ovarian cancer in Italy (Parenteral)
  • 01 Aug 2011 FabOvar licensed to Advanced Accelerator Applications
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top